Cohen Investment Advisors LLC Invests $80,000 in Grifols, S.A. (NASDAQ:GRFS)

Cohen Investment Advisors LLC bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) in the first quarter, HoldingsChannel.com reports. The institutional investor bought 12,014 shares of the biotechnology company’s stock, valued at approximately $80,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GRFS. Capital World Investors raised its position in shares of Grifols by 0.8% in the 4th quarter. Capital World Investors now owns 19,787,525 shares of the biotechnology company’s stock worth $228,744,000 after acquiring an additional 158,474 shares in the last quarter. Brandes Investment Partners LP lifted its position in Grifols by 22.2% during the fourth quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock valued at $156,245,000 after buying an additional 2,454,730 shares during the period. First Trust Advisors LP lifted its position in Grifols by 6.9% during the fourth quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock valued at $54,156,000 after buying an additional 302,380 shares during the period. Norges Bank bought a new stake in shares of Grifols during the 4th quarter valued at $26,137,000. Finally, New York State Common Retirement Fund grew its position in shares of Grifols by 38.5% in the 4th quarter. New York State Common Retirement Fund now owns 2,058,286 shares of the biotechnology company’s stock worth $23,794,000 after buying an additional 572,439 shares during the period.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft lowered shares of Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Grifols Stock Up 1.8 %

NASDAQ:GRFS traded up $0.12 during trading hours on Thursday, reaching $6.64. 436,830 shares of the company traded hands, compared to its average volume of 1,128,496. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The business’s 50-day moving average price is $7.02 and its two-hundred day moving average price is $7.59. The company has a quick ratio of 1.29, a current ratio of 2.79 and a debt-to-equity ratio of 1.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.